From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors

ABSTRACT: Targeted radionuclide therapy is a revolutionary tool for the treatment of cancers. Most current approaches rely on the use of vectors to deliver radionuclides to tumor cells, targeting membrane-bound cancer-specific moieties. Here, we report the netrin-1 as an unanticipated target for vectorized radiotherapy. While netrin-1, known to be re-expressed in tumoral cells to promote cancer progression, is usually characterized as a diffusible ligand, we demonstrate here that netrin-1 is actually poorly diffusible and bound to the extracellular matrix. A therapeutic anti-netrin-1 antibody (NP137) has been tested in various clinical trials. In order to provide a companion test detecting netrin-1 in tumors and allowing selection of therapy-eligible patients, we developed an indium-111-NODAGA-NP13

SUBMITTER: Dr. Patrick Mehlen 

PROVIDER: S-SCDT-10_15252-EMMM_202216732 | biostudies-other |

REPOSITORIES: biostudies-other